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The broad spectrum of selenium applications in pharmacy and medicine has been known 
for a while and strongly depends on its chemical form, size and shape. However, the use of 
Se often requires consumption over the long period, so the toxicity of Se is always a crucial 
concern. Majority of available pharmaceutical products contain organic forms of selenium 
or its salts, but recently, when it comes to cancer treatment, elemental selenium 
nanoparticles (SeNPs) have emerged as a novel selenium source with the advantage of 
reduced risk of selenium toxicity, but with same bioavailability and efficacy in increasing 
the activities of selenoenzimes.  
In this work we are presenting the fast, reproducible method for producing stable colloidal 
suspension of amorphous SeNPs (<80 nm). These SeNPS were successful incorporated 
within PCL microspheres by combining the high speed homogenization and the 
precipitation in a solvent/non-solvent system. The obtained PCL/SeNPs were 
characterized by Fourier transform infrared spectroscopy (FTIR), electron microscopy 
(SEM and TEM), X-ray diffraction (XRD) and thermal analysis methods (TGA-DTA). The 
cytotoxicity and the formation of intracellular reactive oxygen species of SeNPs as well as 
of PCL/SeNPs were investigated employing 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay and using a fluorescent probe (DCFDA test) 
respectively. Both systems have shown good biocompatibility. The anticancer activity of 
SeNPs was examined on the HeLa cell line and it was demonstrated that SeNPs exhibits 
strong, a dose dependent, anticancer activity by preventing further HeLa cells growth and 
division. Bearing in mind that PCL is well known biodegradable polymer with low 
degradation rate, it is our opinion that PCL/SeNPs possess a great potential for cancer 
treatment. 
 
 
